Y
Yikon Genomics
A professional service provider for reproductive and cancer genetic testing
About Yikon Genomics
Yikon Genomics specializes in providing advanced genomic solutions primarily for fertility clinics and oncology research. The company operates in the global healthcare market, offering a range of products and services that leverage its proprietary MALBAC (Multiple Annealing and Looping-Based Amplification Cycles) technology. This technology enables rapid and precise DNA analysis, which is crucial for pre-implantation genetic testing (PGT) and cancer diagnostics.
Yikon Genomics serves fertility clinics, research institutions, and healthcare providers. Its core products include PGTA ChromInst, PGTM ChromSwift, and MaReCs, which are designed to enhance the accuracy and speed of genetic testing. The company’s business model revolves around selling these specialized genomic testing kits and providing associated services. Revenue is generated through the sale of these kits and ongoing service contracts with healthcare providers and research institutions.
The company’s market is highly specialized, focusing on fertility treatments and oncology, where precise genetic information can significantly impact treatment outcomes. Yikon Genomics differentiates itself through its innovative MALBAC technology, which allows for the amplification of single-cell DNA, making it possible to conduct comprehensive genetic analyses quickly and accurately.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- Huangpu, China
- Employees
- 54
- Open positions
- 1
- Dealroom signal
- 49.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Testing, Biotechnology, Biotech and Pharma, Hard Tech, medical testing, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | May 2021 | $34M | $138M | General Technology Venture Capital · Oriza Holdings · YunFeng Capital · Sinopharm Capital | — |
| SERIES COther financing | Nov 2019 | $31M | $124M | KingMed Diagnostics · Guangzhou YUEXIU Industrial Investment Fund | — |
Growth signals
Latest recorded traffic for Yikon Genomics is 2.3K monthly website visits, up 2775% over the last three months. Yikon Genomics's team grew 3.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later6 investors entered at this stage
KingMed Diagnostics- GFGuangzhou YUEXIU Industrial Investment Fund
- GCGeneral Technology Venture Capital
Oriza Holdings
YunFeng Capital- SCSinopharm Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Yikon Genomics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Yikon Genomics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.